ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 708

Development of an Activity Disease Score in Patients with Uveitis

Esperanza Pato Cour1, Maria Auxiliadora Martin2, Santiago MuÑoz Fernandez3, Adela Castello4, Fernando Sanchez-Alonso5, David Diaz-Valle6, Rosalía Mendez7 and Uveitis MeVa Group, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, 3Rheumatology, Hospital Infanta Sofía, Madrid, Spain, 4Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain, Madrid, Spain, 5Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, 6Hospital Clínico San Carlos de Madrid, Madrid, Spain, 7Ophthalmology, Hospital Clínico San Carlos, Madrid, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Activity score and uveitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Uveitis is commonly defined as inflammation of the uvea, the vascular middle layer of the eye. Standardized and validated outcome measures are lacking in uveitis management, which makes it difficult to compare the efficacy and responses to treatment.

To develop a disease activity score for patients with uveitis and determine its discriminating ability to classify patients based on the level of activity. 

Methods: Multicenter cross-sectional observational study. The construct “uveal inflammation activity” was defined as intraocular inflammation. 7 dimensions and 14 items were identified and were agreed among experts through a two-round Delphi technique. The dimensions were: visual acuity, anterior chamber, vitreous cavity and posterior segment inflammation, uveitic macular edema, patient and physician global assessment. 8 Spanish hospitals with uveitis units participated in the study. Patients diagnosed with uveitis, older than 5 years and inflammatory activity at the time of the visit, were selected. Primary endpoint: uveitis inflammatory activity, defined as any intraocular inflammation and categorized as mild, moderate and severe. An ordinal logistic regression model was built whose dependent variable was the inflammatory activity (mild, moderate, severe). The modelling accuracy to classify the patient in the right category was assessed with the Area Under the Curve (AUC). Two AUC measures were calculated: one for the discrimination of mild versus moderate and severe activity level of uveitis and another for the discrimination of mild and moderate versus severe activity. 

Results: 195 patients were included, 54% were women and the mean age was 45.8±16.1 years. The results of the regression model revealed that the uveitis was more severe in patients with an elevated number of anterior chamber cells (OR4 cells vs 0cells=27.85;95%CI=3.42;226.75), high degree of vitreous haze (ORsevere vs null=3.95;95%CI=1.40;11.16), macular edema over 315 micras (OR>315 vs ≤315=3.58;95%CI=1.56;8.21), presence of vessel sheathing (ORyes vs no=4.43;95%CI=1.71;11.53), higher patient’s evaluation (OR1-unit increase=1.23;95%CI=1.09;1.39), presence of papilitis (ORyes vs no=4.05;95%CI=1.18;13.92) and elevated number of choridal or retinal lesions (OR≥6 vs 0=4.99;95%CI=1.08;23.01). The discriminant capacity of disease activity index is 87% (95%CI:82%-92%) for discriminating patients with mild uveitis from patients with moderate or severe uveitis and 88%(95%CI:84%-95%) for discriminating patients with mild or moderate uveitis from patients with severe uveitis.

Conclusion: This composite disease activity index in uveitis integrates all ocular inflammatory activity and takes into account the assessment of the patient and the doctor. The index has a high capacity to classify the inflammatory activity of the patients with uveitis.


Disclosure: E. Pato Cour, None; M. A. Martin, None; S. MuÑoz Fernandez, None; A. Castello, None; F. Sanchez-Alonso, None; D. Diaz-Valle, None; R. Mendez, None.

To cite this abstract in AMA style:

Pato Cour E, Martin MA, MuÑoz Fernandez S, Castello A, Sanchez-Alonso F, Diaz-Valle D, Mendez R. Development of an Activity Disease Score in Patients with Uveitis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/development-of-an-activity-disease-score-in-patients-with-uveitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-an-activity-disease-score-in-patients-with-uveitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology